🚀 Excelya helps Sensorion meet FPI goal on time in Phase IIa Oncology trial

Job Description

Sensorion is seeking a professional for a clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.

The exploratory phase 2a, multicenter, randomized, controlled, open-label study, NOTOXIS, aims at evaluating the efficacy of SENS-401 to prevent ototoxicity induced by cisplatin in adult patients with a neoplastic disease.

Responsibilities:

• Evaluate the efficacy of SENS-401 to prevent ototoxicity induced by cisplatin in adult patients with a neoplastic disease.
• Assess SENS-401 efficacy measuring the change from baseline of the average of the pure tone audiometry (PTA) four weeks after the completion of cisplatin treatment.
• Assess secondary outcome measures, including the rate and severity of ototoxicity, and the change in PTA (dB) throughout the study and tolerance.

Qualifications:

• Experience in clinical trials, preferably in oncology.
• Knowledge of ototoxicity and its prevention.
• Ability to evaluate and assess clinical data.

Sensorion is an equal opportunities employer and welcomes applications from all qualified candidates. We are committed to providing a workplace that is free from discrimination and harassment, and where all employees are treated with dignity and respect.